Healthcare AI & Digital Health — 2026年11月2日 週次レポート
Healthcare AI & Digital Healthのニュース＆アップデート — すべての記述に一次ソースのリンク付き。
重要な発見
エグゼクティブサマリー（5件）
- •The week's regulatory activity was dominated by two opposing forces: a federal court blocking a key component of Medicaid work requirements just weeks before the January 2027 implementation deadline, and the administration finalizing two major deregulatory rules (DOL PBM transparency and HHS HTI-5) that together project over $23 billion in system-wide savings. The simultaneous judicial constraint on coverage reduction and administrative push for cost transparency reflects a healthcare policy env…
- •Clinical AI crossed a threshold from adoption to scale this week. OpenEvidence's systemwide NYU Langone deployment — its fourth major NYC academic medical center — combined with UnitedHealthcare's Avery expansion to 21 million members and a JAMA study documenting 271 million AI-enabled clinical queries, signals that AI is no longer a pilot technology in healthcare. The AMA's liability framework and AdvaMed's data access principles, released in the same week, represent the governance infrastructu…
- •The ambulatory surgery consolidation wave intensified with Bon Secours Mercy Health's $5.7 billion Surgery Partners acquisition, following Ascension's $3.9 billion AmSurg deal. Combined with Tenet's strong Q3 results and the ongoing shift of elective procedures out of hospitals, the structural reorientation of surgical care delivery toward lower-cost outpatient settings is now producing large-scale M&A that will reshape competitive dynamics for years.
- •The GLP-1 and metabolic health ecosystem is expanding beyond the drug itself: Eli Lilly's retatrutide Phase 3 data showing superiority over Ozempic on both glycemic control and weight loss, Oura's clinical trial linking wearable data to GLP-1 outcomes, and PMDA's safety alert on GLP-1 proper use collectively signal that the category is maturing into a multi-product, multi-modality, globally regulated market with intensifying safety scrutiny.
- •The Ebola outbreak's geographic expansion to Kenya and Nigeria — requiring ECDC expert deployment — combined with the approaching RSV season and ECDC's first-ever public health emergency preparedness assessments revealing recurring challenges across Europe, underscores that global infectious disease surveillance infrastructure is under sustained multi-pathogen pressure at a moment when health system capacity is already strained.
今回の要点（18件）
- 1.FDA approved the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis on October 30, marking a novel therapeutic modality milestone [2a].
- 2.A Massachusetts federal judge issued a permanent injunction on October 29 against CMS's definition of 'medical frailty' for Medicaid work requirement exemptions, granting states a six-month stay of enforcement [3a].
- 3.The DOL finalized a PBM transparency rule on October 29 requiring disclosure of fees, rebates, and spread pricing to self-funded employers, projecting up to $22 billion in savings over 10 years [3b].
- 4.HHS finalized the HTI-5 health IT deregulation rule on October 26, removing 14 of 60 certification criteria and projecting $1.55 billion in present-value regulatory savings beginning in 2027 [3c].
- 5.Bon Secours Mercy Health announced a $5.7 billion take-private acquisition of Surgery Partners on October 26, creating one of the country's largest outpatient surgical care platforms [3d].
- 6.OpenEvidence deployed its clinical AI platform systemwide at NYU Langone Health, adding to existing deployments at NewYork-Presbyterian, Mount Sinai, and Memorial Sloan Kettering; a JAMA study found nearly 1 million U.S. clinicians submitted 271 million AI-enabled queries through the platform from January 2024 to June 2026 [3e].
- 7.UnitedHealthcare expanded its generative AI companion Avery to 21 million members, up from 6.5 million, after finding the tool resolved 90% of member interactions [3f].
- 8.Eli Lilly's retatrutide posted Phase 3 results showing it beat Ozempic on A1C reduction (2.2 vs. 1.8 percentage points) and weight loss (up to 20.9% vs. 9.4%) in type 2 diabetes [5a].
- 9.MHRA approved Casgevy gene-editing treatment extension for children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia on October 30 [9].
- 10.Aetna joined Centene and Alignment Healthcare in suing CMS over 2027 Medicare Advantage star ratings, estimating $2 billion in lost quality bonus payments [3g].
- 11.ECDC deployed experts to Nigeria on October 27 as Ebola disease emerged in Kenya and Nigeria, with the DRC situation remaining serious [8].
- 12.ECDC published a report on October 28 indicating universal RSV immunisation of newborns could substantially reduce infant hospitalisations across Europe during the winter season [8].
- 13.Teladoc Health raised its 2026 revenue outlook to $2.39–$2.44 billion after Q3 beat expectations, with BetterHelp insurance revenue reaching $32.1 million, up from $3.7 million a year ago [3h].
- 14.Walmart launched an expanded Better Care Services healthcare marketplace with General Medicine, enabling consumers to compare more than 900 products and services with insurance cost transparency [3i].
- 15.The AMA released a clinical AI liability framework on October 29 distributing accountability across developers, deploying organizations, and physicians based on ability to prevent harm [10].
- 16.AdvaMed approved voluntary Data Access Principles & Best Practices for medtech-health system data sharing on October 28, establishing common expectations for AI-enabled technology deployments [11a].
- 17.PMDA issued a new alert on October 30 requesting proper use of GLP-1 receptor agonists and GIP/GLP-1 receptor agonists [4].
- 18.A NEJM AI study found large language models recommend care costing a mean of $314 per visit versus $97 for attending physicians — more than three times the cost — across 20 general-purpose AI systems tested on 200 real patient visits [3j].
市場動向
Clinical AI Deployment Accelerates Into EHR Workflows at Scale
The week's activity reveals a decisive shift from AI as a standalone tool to AI embedded directly inside clinical workflows. OpenEvidence expanded its EHR-integrated platform systemwide at NYU Langone Health — covering more than 12 million outpatient visits annually — building on existing deployments at NewYork-Presbyterian, Mount Sinai, and Memorial Sloan Kettering [3e]. A JAMA study cited in the same report found nearly 1 million U.S. clinicians submitted 271 million AI-enabled clinical querie…
FDA Approvals Signal Biotech Innovation Across Novel Modalities
The FDA approved the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis on October 30, and the FDA's press announcements page confirmed multiple October approvals including a first-of-its-kind chronic hepatitis B treatment and an immunotherapy allowing certain rectal cancer patients to avoid chemotherapy, radiation, and surgery [2a]. The MHRA approved an extension of Casgevy (exagamglogene autotemcel) gene-editing treatment for children aged five and over …
Ambulatory Care Consolidation Accelerates as Health Systems Reposition
Bon Secours Mercy Health announced a $5.7 billion take-private acquisition of Surgery Partners, which would create one of the country's largest outpatient surgical care platforms with more than 200 locations across 30 states [3d]. This follows Ascension's $3.9 billion AmSurg close over the summer. Tenet Healthcare reported Q3 net operating revenues of $5.63 billion, up 6.5% year-over-year, with executives noting the ambulatory surgery market is heating up as health systems flesh out their networ…
GLP-1 Ecosystem Expands Beyond Weight Loss Into Monitoring and Maintenance
The GLP-1 market is evolving from a drug-centric story to a broader ecosystem. Oura launched its first clinical trial (SMART-BMI) with UC San Diego Health to study whether continuous smart ring data — including sleep, heart rate, and activity — are associated with outcomes for patients receiving GLP-1 medications or bariatric surgery [3l]. PMDA issued a new alert on October 30 requesting proper use of GLP-1 receptor agonists and GIP/GLP-1 receptor agonists [4]. Corxel Pharmaceuticals announced a…
Healthcare Affordability Pressure Intensifies as Coverage Erosion Continues
KFF Health News reported that millions of Medicare enrollees buying stand-alone prescription drug plans will see average monthly premiums rise by 50% in 2027 [6]. A Morning Consult poll commissioned by HFMA found 54% of 2,022 registered voters said healthcare has become less affordable in 2026, with majorities of both parties saying affordability will affect their midterm vote [5c]. Community Health Systems reported an $86 million net loss in Q3 2026, citing elevated uninsured volumes and soft c…
競合動向
OpenEvidence and Clinical AI Search Platforms Race to Become the Standard of Care Layer
OpenEvidence's systemwide deployment at NYU Langone — its fourth major New York City academic medical center partnership — combined with a reported 1.2 million medical license-verified U.S. clinicians and 45 million verified consultations in October alone, positions it as the dominant clinical AI search platform [3e]. Vera Health secured $28.5 million in Series A funding led by Threshold Ventures, with Optum Ventures participating, to expand its evidence-based clinical search engine used by more…
Teladoc and Virtual Care Platforms Pivot to Insurance Integration and Outcome-Based Models
Teladoc Health raised its 2026 full-year revenue outlook to $2.39–$2.44 billion after Q3 results beat expectations, driven by BetterHelp's insurance pivot gaining traction — commercial insurance revenue reached $32.1 million in Q3, up from $3.7 million a year ago, with 27,000 covered sessions per week [3h]. Teladoc also acquired Teledigm Health to bring its hybrid care model — combining technology with virtual clinical services delivered into physical healthcare settings — to U.S. hospitals and …
Walmart and Retail Health Platforms Reposition as Healthcare Marketplaces
Walmart launched an expanded Better Care Services platform in partnership with General Medicine — founded by the PillPack and Amazon Pharmacy team — enabling consumers to search and browse more than 900 products and services, compare out-of-pocket costs with and without insurance, and connect to care [3i]. General Medicine had raised $120 million in Series B funding earlier in October. The model positions Walmart as a healthcare marketplace operator rather than a care provider — a strategic pivo…
MHRA Approves Gene Editing and Rare Disease Therapies, Signaling UK as Innovation Hub
MHRA approved an extension of Casgevy (exagamglogene autotemcel) for children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia on October 30, and approved triheptanoin (Dojolvi) for adults and children with a group of rare inherited disorders on the same date [9]. MHRA also published new research on a needle-free Strep A vaccine approach on October 27. These approvals, combined with the prior week's indefinite CE mark recognition, position the UK as an i…
AMA Advances Clinical AI Liability Framework, Reshaping Developer and Deployer Obligations
The AMA released a clinical AI liability framework on October 29–30 that distributes accountability across developers, deploying healthcare organizations, and physicians based on each party's ability to prevent harm [10]. The framework states physicians should be responsible for clinical judgment they can meaningfully exercise, and should retain the authority to decline unproven AI systems without organizational penalty [3o]. AdvaMed simultaneously approved voluntary Data Access Principles & Bes…
制度・規制動向
FDA Approves First Plasmid DNA-Based Immunotherapy and Launches Neuroscience Program
The FDA approved the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis on October 30, marking a novel therapeutic modality milestone [2a]. The FDA's neuroscience medical product development program, launched October 22 with an inaugural Alzheimer's Prevention Accelerator focus, continues to build cross-center infrastructure for complex neurological conditions [2a]. Upcoming FDA events include a public meeting on transcranial ultrasound for neurological an…
Medicaid Work Requirements Face Judicial Setback as January 2027 Deadline Looms
A Massachusetts federal judge ruled on October 29 that CMS's definition of 'medical frailty' for Medicaid work requirement exemptions unlawfully limited the group qualifying for exemptions, issuing a permanent injunction and granting states a six-month stay of enforcement on frailty determinations [3a]. The AMA called the ruling a victory for patients on October 29 [10]. States including New Jersey and Illinois reported that thousands of immigrants have already lost coverage this month, with Ill…
DOL Finalizes PBM Transparency Rule, Projecting $22 Billion in Savings Over 10 Years
The Department of Labor's Employee Benefits Security Administration finalized a rule on October 29 requiring pharmacy benefit managers to disclose fees and compensation — including manufacturer rebates, spread pricing arrangements, and payments recouped from pharmacies — to self-funded employers [3b]. The DOL projected the rule will lower prescription drug costs for health plans by up to $22 billion over 10 years [5d]. The Pharmaceutical Care Management Association argued the rule exceeds Congre…
HHS Finalizes HTI-5 Rule Projecting $1.55 Billion in Health IT Compliance Savings
HHS's Office of the National Coordinator for Health IT finalized the HTI-5 rule on October 26, removing 14 out of 60 certification criteria and revising seven, projected to save $1.55 billion in present-value regulatory costs and $108.1 million in annualized net savings beginning in 2027 [3c]. The rule also removed AI model-card transparency requirements for decision support interventions established under HTI-1, and signals ONC's shift toward FHIR-based API certification. Information blocking p…
ECDC Deploys Experts to Nigeria as Ebola Outbreak Expands; RSV Immunization Report Released
ECDC announced on October 27 it is sending a team of experts to Nigeria following the emergence of Ebola disease in Kenya and Nigeria, with the DRC situation remaining serious [8]. On October 28, ECDC published a report indicating that universal immunisation of newborns against RSV could substantially reduce infant hospitalisations across Europe during the winter season [8]. On October 29, ECDC published results from the first cycle of Public Health Emergency Preparedness Assessments across Euro…
ソース活動
先週からの変化
FDA Approves First Plasmid DNA-Based Immunotherapy; Multiple Novel Approvals This Week
FDA approved the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis on October 30 [2a]. The FDA's October press announcements also confirmed a first-of-its-kind chronic hepatitis B treatment (Oct 20), an immunotherapy allowing certain rectal cancer patients to avoid chemotherapy and surgery (Oct 19), and a first heart valve designed to grow with children (Oct 1). MHRA approved Casgevy gene-editing treatment extension for children aged five and over with si…
Medicaid Work Requirements Medical Frailty Definition Struck Down by Federal Court
A Massachusetts federal judge issued a permanent injunction on October 29 against CMS's definition of 'medical frailty' for Medicaid work requirement exemptions, ruling it unlawfully limited the group qualifying for exemptions and granted states a six-month stay of enforcement on frailty determinations [3a]. The AMA called the ruling a victory for patients [10]. States are racing to implement H.R. 1 changes ahead of the January 1, 2027 work requirements rollout, with New Jersey and Illinois alre…
DOL Finalizes PBM Transparency Rule; HHS Finalizes HTI-5 Health IT Deregulation Rule
The DOL finalized a PBM transparency rule on October 29 requiring disclosure of fees, rebates, and spread pricing to self-funded employers, projecting up to $22 billion in savings over 10 years [3b]. HHS finalized the HTI-5 rule on October 26, removing 14 of 60 health IT certification criteria and projecting $1.55 billion in present-value regulatory savings beginning in 2027 [3c]. Both rules represent significant new regulatory actions affecting digital health and pharmaceutical benefit manageme…
Bon Secours Mercy Health Acquires Surgery Partners in $5.7B Deal; Ambulatory M&A Accelerates
Bon Secours Mercy Health announced a $5.7 billion take-private acquisition of Surgery Partners on October 26, creating one of the country's largest outpatient surgical care platforms with more than 200 locations across 30 states [3d]. The deal follows Ascension's $3.9 billion AmSurg close over the summer and reflects large health systems' strategic push to build ambulatory networks as care migrates out of hospitals.
AMA and AdvaMed Release Clinical AI Accountability Frameworks; MA Star Ratings Litigation Expands
The AMA released a clinical AI liability framework on October 29 distributing accountability across developers, deploying organizations, and physicians [10]. AdvaMed approved voluntary Data Access Principles & Best Practices for medtech-health system data sharing on October 28 [11a]. Separately, Aetna joined Centene and Alignment Healthcare in suing CMS over 2027 Medicare Advantage star ratings, estimating $2 billion in lost quality bonus payments [3g]. The AI governance and MA litigation fronts…
ウォッチリスト — 今後の締切
FDA Public Meeting - Challenges and Solutions in Lot-Level Food Traceability
ソース: FDA NewsFDA and Focused Ultrasound Foundation Co-sponsored Public Workshop: Research Roundtable on Transcranial Ultrasound for Neurological and Psychiatric Applications
ソース: FDA NewsFDA/CRCG Workshop on Long-Acting Injectable (LAI) Generics: Advancing Innovation in Product Development and Regulatory Assessment
ソース: FDA News示唆・見るべき論点（9件）
- 1.The DOL PBM transparency rule's projection of up to $22 billion in savings over 10 years [3b] creates an immediate compliance obligation for PBMs serving self-funded employer plans. Companies should audit their current disclosure practices against the new requirements before the rule takes effect, as the ERISA Industry Committee has signaled it will use the rule to demand detailed accounting of spread pricing arrangements.
- 2.The federal court's permanent injunction on CMS's medical frailty definition [3a] does not stop work requirements — it narrows the exemption criteria. Health plans and states should model enrollment scenarios under both the injunction's frailty standard and the CMS definition to understand the range of potential membership impacts ahead of January 2027.
- 3.The NEJM AI study finding that LLMs recommend care costing more than three times what attending physicians recommend [3j] is a direct challenge to the value proposition of AI clinical decision support. Companies deploying AI tools in clinical settings should proactively conduct cost-of-care analyses of their tools' recommendations to get ahead of payer and regulatory scrutiny.
- 4.The AMA's clinical AI liability framework explicitly states physicians should retain the authority to decline unproven AI systems without organizational penalty [3o]. Health systems deploying AI tools should review their governance policies to ensure they do not create implicit or explicit pressure on physicians to use AI tools whose clinical validation remains uncertain — a practice the AMA framework would characterize as inappropriate.
- 5.Teladoc's BetterHelp insurance pivot — commercial insurance revenue up from $3.7 million to $32.1 million year-over-year [3h] — demonstrates that the transition from cash-pay to insurance-covered virtual mental health is commercially viable at scale. Digital mental health companies still operating primarily on cash-pay models should accelerate credentialing and payer contracting strategies.
- 6.AdvaMed's voluntary Data Access Principles & Best Practices [11a] establish a de facto industry standard for medtech-health system data sharing agreements. Companies that adopt these principles proactively will have a contracting advantage over those that do not, as health systems increasingly use them as a baseline expectation in technology procurement.
- 7.The Bon Secours-Surgery Partners deal's structure — with Bain Capital retaining its 39% stake while HealthSpan Partners acquires the remainder — signals that private equity is not exiting ambulatory surgery but rather partnering with health systems to access their patient referral networks [3d]. Independent ambulatory surgery center operators should expect continued consolidation pressure from both health system and private equity acquirers.
- 8.PMDA's GLP-1 proper use alert [4] signals that Japanese regulators are responding to off-label cosmetic use of diabetes medications — a pattern also seen in the MHLW's prior warnings about Manjaro and Rybelsus. Companies marketing GLP-1 products in Japan should review their promotional materials and distribution controls to ensure compliance with the alert's requirements.
- 9.The HTI-5 rule's removal of AI model-card transparency requirements for decision support interventions [3c] reduces one compliance burden for AI developers but may increase scrutiny from health systems and payers who relied on those disclosures for procurement decisions. Companies should consider voluntarily maintaining model card documentation as a competitive differentiator even without the regulatory mandate.
信頼度サマリー
今週引用したソース 19 件あなたが選んだ 30 件の監視URLから検出（1つのURLから複数記事が出ることがあります）。
各ソースは信頼度レベルに応じて重み付けされています。単独ソースの主張は AI 合成時に未検証としてフラグ付けされます。
参照ソース一覧
WHO publications this week including public health advice on gender considerations during Ebola outbreaks (Oct 28), tobacco and infertility knowledge summary (Oct 28), target regimen profiles for long-acting injectables for TB (Oct 26), and TB drug resistance mutation catalogue (Oct 30).
FDA press announcements including first plasmid DNA-based immunotherapy approval for recurrent respiratory papillomatosis (Oct 30), neuroscience medical product development program launch (Oct 22), final guidance on prescription drug apps (Oct 20), first-of-its-kind chronic hepatitis B treatment approval (Oct 20), and rectal cancer immunotherapy approval (Oct 19). Upcoming events include FDA/Focused Ultrasound Foundation workshop on transcranial ultrasound (Nov 10) and LAI generics workshop (Dec 1).
Reporting on Bon Secours-Surgery Partners $5.7B deal, Walmart-General Medicine Better Care Services launch, UnitedHealthcare Avery expansion to 21M members, OpenEvidence NYU Langone deployment, Teladoc Q3 results and BetterHelp insurance pivot, DOL PBM transparency rule finalization, HTI-5 rule finalization, Medicaid work requirements court ruling, Aetna MA star ratings lawsuit, UT Dell Medicine AI-native hospital plans, Vera Health $28.5M Series A, ClarityCare $16.5M Series A, Oura GLP-1 clinical trial, AMA clinical AI liability framework, and multiple hospital Q3 earnings reports.
PMDA updates including new GLP-1 receptor agonist proper use alert (Oct 30), English translation of Zurzuvae review report (Oct 29), new risk communications for Tapinarof and revisions of precautions for Inclisiran sodium (Oct 27), and updated list of approved regenerative medical products (Oct 26).
Reporting on Eli Lilly retatrutide Phase 3 results beating Ozempic, Corxel oral GLP-1 SPAC merger, Lycia $317M IPO, Bambusa $169M IPO for bispecific antibodies, Aspen Neuroscience $140M IPO for Parkinson's cell therapy, Artiva cell therapy program halt after patient fatalities, Sutter Health heart failure remote monitoring expansion, DOL PBM rule employer advocacy reactions, HFMA healthcare affordability declaration, and Setara Biosciences $90M Series A.
KFF Health News reporting on Medicare drug plan premium increases of 50% in 2027 (Oct 30), hospital beds for critically ill children disappearing (Oct 28), healthcare cost hitting Americans' wallets (Oct 26), and health worries animating midterm campaigns (Oct 29).
Cochrane review published October 28 finding ergonomic interventions show no meaningful benefit for pain, function, recovery or sick leave in workers with work-related arm, neck or shoulder complaints.
ECDC deployed experts to Nigeria as Ebola cases emerged in Kenya and Nigeria (Oct 27); published report on universal RSV immunisation of newborns reducing infant hospitalisations (Oct 28); published first cycle of Public Health Emergency Preparedness Assessments showing common challenges across Europe (Oct 29).
MHRA approved Casgevy gene-editing treatment extension for children aged five and over with sickle-cell disease and β-thalassemia (Oct 30), approved triheptanoin (Dojolvi) for rare inherited disorders (Oct 30), published needle-free Strep A vaccine research (Oct 27), and updated clinical trials hub with six-month implementation blog (Oct 29).
AMA advanced framework for clinical AI liability on October 29 calling for clear accountability; AMA statement on medical frailty ruling calling it a victory for patients (Oct 29); physician organizations backed new challenge to Medicaid work rule (Oct 27); AMA urged FDA to pursue safety standards for botanical products (Oct 30).
AdvaMed Digital Health Tech Board approved voluntary Data Access Principles & Best Practices for medtech-health system data sharing (Oct 28); AdvaMed encouraged risk-based FDA approach to generative AI medical devices (Oct 27); AdvaMed concluded record-breaking MedTech Conference 2026 with 4,470 attendees from 2,050 companies (Oct 28).
Epic published article on nationwide diagnostic image exchange through TEFCA (Oct 27) and reported a UK trust collaboration saving £4.1 million and 275,000 hours of nursing time over three years (Oct 26).
NICE published articles on new AI tools to help spot prostate cancer more accurately, recommended Enhertu for HER2-low advanced breast cancer, and published draft guidance to improve identification of OCD and body dysmorphic disorder.
CVS Health published Aetna provider survey showing payer-provider trust score of 6 out of 10 in Q3, with 50% of providers believing insurers support patient well-being and 30% recommending AI to identify fraudulent claims (Oct 26).
Boston Scientific announced Q3 2026 net sales of $5.138 billion, growing 1.5% on a reported basis (Oct 28), and announced participation in Stifel's 2026 Healthcare Conference (Oct 26).
BD advanced portal hypertension care with launch of Liverty TIPS Stent Graft giving physicians flexibility to tailor treatment for patients (Oct 28).
Philips launched UniGuide 3D Live Guidance bringing CT planning into live procedures and extending Azurion image-guided therapy platform capabilities (Oct 29); published article on turning Europe's Safe Hearts Plan into action (Oct 30).
Stryker completed acquisition of ZuriMED to enhance its shoulder offering (Oct 26) and published article on managing growing colonoscopy demand with Neptune S technology (Oct 27).
MHLW updates including security alert on unauthorized access and information leakage (Oct 30), influenza and COVID-19 surveillance data updates (Oct 30), three new designated substances for dangerous drugs (Oct 27), and physician working style reform committee meeting announcement (Oct 26).
Healthcare AI & Digital Healthを毎週、自動で監視
このレポートは一次ソースのみから生成されています。テーマとソースを選べば、引用付きレポートが毎週届きます。7日間無料トライアル・$33/月から。
無料トライアルを始める